From the Editor: November-December 2024

Cheryl Scott, Editor in Chief.

BPI is poised to enter its 23rd year in print. The 21st century has brought many changes to publishing(e.g., from online presence as a “value-add” to an essential) but throughout the decades, some things remain the same for us. We’ve always sought to empower our readers to anticipate, identify, and solve problems in bringing biopharmaceuticals to market around the world. We provide you with an access point to experts and best practices, a resource for discovering the latest technological options, and a forum for discussing business, regulatory, and scientific trends. By targeting key challenges and sharing solutions, BPI provides tailored support to help you make strategic decisions and optimize bioprocesses.

Our mission remains the same even if the industry has changed along the way. Biologic modalities have evolved and matured, bringing new options to the medical toolbox for treating some of the most serious conditions that plague our species. Biotechnologies and other advances have enabled drug discovery, development, testing, and manufacturing in ways never considered in the 20th century. The Human Genome Project has informed medical research, powerful analytical methods have expanded our understanding of biological products and processes, and technology providers have innovated bioprocessing and manufacturing.

BPI in 2025 will continue to address mainstay topics with our regular issue themes (upstream production, downstream processing, product development, advanced therapies, and outsourcing), with narrowed focus in our featured report supplements and eBook series. All depend on your participation as readers, advisors, and contributors.

Our featured reports will be distributed digitally every other month beginning with vaccines in February, then cell-line development (April), drug-product manufacturing (June), facility issues (August), scale-up and technology transfer (October), and gene therapy (December). Monthly eBooks from BPI and BioProcess Insider will highlight ADCs (January), outsourcing (February), process-related impurities (March), biologic modalities (April), process intensification (May), biomanufacturing capacity (June), chromatography (July), exosomes (August), allogeneic cell therapy (September), autologous cell therapy (October), antibody engineering (November), and the biopharmaceutical industry in Asia (December).

We’ve streamlined our schedule of planned themes for 2025 to present timely special projects as they arise and draw interest. An early eBook on bioreactor design and operations is in the works already, and BPInsider’s Shreeyashi Ojha is exploring a project on bioprocessing in India. Stay tuned for more — and consider this your invitation to approach us with your ideas!